Testimonials
sceptical at firs...
« I was unsure of using this service but I am glad I did, Yurity is great to deal with and my g ...»


Warren Australia

Noopept
« Very good deal, fast shipping, very kind, great friends, I will buy again, a 10 !!!»


Anibal España

Perfect, all is c...
« Just recieved my De-nol. It's take 10 days from order. I'm very satisfied of you guys. Thank ...»


Ivan Bulgaria

just received my ...
«
just received my order this m ...»


Patrice... Livry G...

Brilliant!
« Hi, today my friend has received the package and it's all right. No damages and no problems a ...»


Marcello S. Arse...

« Hi, today my friend has received the package and it's all right. No damages and no problems a ...»


Marcello Milan

Thank you!
« Hello, I have received the package, I will recommend you without hesitation, thank you for ev ...»


Dominique Doral

Was really satisf...
« It seems like you guys really understand what you are doing and provide good quality products ...»


Alex Woodmere

We can trust it!
« Thank you guys, I've got my order in 10 days after the payment! The products are origin and e ...»


David New York

« Amazing company, the parcel came to States in 10 days after the payment! Thank you!»


Charles Miami

Depo-Provera 150mg 1 vial 1ml

Depo-Provera 150mg 1 vial 1ml

Brand: Pfizer Inc.
Product Code: 205
Availability: In Stock
Price: $22.00
Qty:     - OR -  
DELIVERY WITHIN 9-11 DAYS.
DEPO-PROVERA. About the drug:
 
Anticancer, a progestin drug. In addition, Depo - provera
 
used as a means of contraception.
 
Indications and dosage:
 
The drug is used in Oncology practice in these States:
 
Recurrences and/or metastases of breast cancer and endometrial

Recurrence and/or metastasis of kidney cancer

Metastasis of prostate cancer

In addition, the drug used in gynaecological practice for the treatment of patients with endometriosis and vasomotor manifestations in menopause.
 
The drug is also prescribed to women of childbearing age as a means of contraception.
 
Before use, a disposable syringe or vial should be shaken until a homogeneous suspension. In applying the drug must comply with the rules of asepsis. The suspension is injected in the gluteal or deltoid muscle if the doctor has not appointed otherwise.
 
The duration of treatment and the dose determined by the attending physician individually for each patient.
 
When breast cancer is usually administered on 500-1000mg of drug per day for 28 days, then move on to the introduction of 500 mg of the drug 2 times a week.
 
Therapy is carried out until until the drug has the desired therapeutic effect.
 
In kidney cancer of the endometrium and is usually administered at 400-1000mg of the drug 1 once a week. If there is a positive dynamics (comes improvement and achieves stabilization of the process) move on to the introduction of 400 mg of the drug 1 time per month.
 
When metastatic prostate cancer is usually prescribed 500 mg of the drug 2 times a week for 3 months, then move on to the introduction of 500 mg of the drug 1 once a week.
 
In applying the drug in gynecological practice for the treatment of women in postmenopause (including in combination with estrogens) should be prescribed a short course under the supervision of a doctor.
 
With endometriosis is usually prescribed for 50mg of the drug 1 once a week or 100mg of the drug 1 time in 2 weeks. The duration of treatment is usually 6 months.
 
When vasomotor manifestations in menopause is usually prescribed at 150mg 1 time in 12 weeks.
 
As a method of contraception is usually prescribed at 150mg of the drug 1 every 3 months. The first injection should be undertaken within 1-5 days of the normal menstrual cycle or after 5 days after delivery (if the patient is not breastfeeding). It is also possible the drug after cessation of breastfeeding or 6 weeks after childbirth (in case the avoidance of breastfeeding is not possible). Before administering the drug as a method of contraception should be deleted from the patient of malignant tumors of the cervix and breast.
 
To maintain the desired concentration of drug in the blood and maintain a high degree of protection from unwanted pregnancy and subsequent injections are recommended every 12 weeks (a maximum of 89 days).
 
In the case of thromboembolism should decide the question of whether further treatment with the drug Depo-provera.
 
Overdose:
 
When applying high doses of medication used for the treatment of patients with malignant tumors may develop symptoms of an overdose of glucocorticoids (should monitor the patient's condition and, if necessary, reduce the dose of the drug)
 
Cases of acute drug overdose were reported.
 
Side effects:
 
Side effects that developed during therapy with the drug, was largely due to the dose and frequency of treatment, depending on the nature of the disease of the patient.
 
When using the drug in oncological and gynecological practice were noted such side effects:
 
The gastro-intestinal tract: nausea, cholestatic jaundice. In addition, when use of the drug in cancer patients showed development of vomiting, stool disorders, dryness of the oral mucosa, impaired liver function.
 

In the Central and peripheral nervous system: headache, dizziness, violation of sleep and wakefulness, impaired concentration, emotional lability, impaired vision, and convulsions.
 

From the cardiovascular system and the hemopoietic system: embolism of different localization. In addition, in applying the drug in oncologic practice, patients noted the development of hypertension, palpitation, heart rhythm disorders, heart failure, cerebral infarction and infarction, thrombophlebitis, thrombosis of arteries of the retina, increasing the amount of platelets and leukocytes.
 

With the genitourinary system: in women, noted the development of menstrual cycle, including change the duration of a cycle and a violation of regularity, amenorrhea, prolonged anovulation and changing the cervical secretion.
 

From breast cancer: enhanced sensitivity, mastodynia and galactorrhea.
 

Allergic reactions: skin rash, itching, hives, Quincke's edema, anaphylactic shock.
 

Other: alopecia, acne, hirsutism, edema of extremities, fever, pain at the injection site, changes in body weight. In addition, when using drugs in gynecology women noted the development of reduced tolerance to glucose. In applying the drug in Oncology may develop cushingoid syndrome, a decrease in the activity of the adrenal glands, ACTH and hydrocortisone in the blood.
 

When using the drug as a method of contraception were noted such side effects:
 
The gastro-intestinal tract: nausea, epigastric pain, flatulence, disorders of liver function, jaundice, including symptoms of cholestasis.
 

In the Central and peripheral nervous system: headache, dizziness, violation of sleep and wakefulness, impaired concentration, emotional lability, convulsions, impaired vision (with the development of severe visual impairment the drug should be discontinued).
 

From the cardiovascular system and the hemopoietic system: embolism of different localization.
 

With the genitourinary system: menstrual irregularities, including changing the length of a cycle and a violation of regularity, amenorrhea, prolonged anovulation, leucorea, recurrent pain in the pelvis and change in cervical secretion. In addition, in some cases, noted the development of vaginitis.
 

From breast cancer: enhanced sensitivity, mastodynia and galactorrhea.
 

Allergic reactions: skin rash, itching, hives, Quincke's edema, anaphylactic shock.
 

Other: alopecia, acne, hirsutism, edema of extremities, fever, pain at the injection site, changes in body weight, in a few cases, a decrease in libido and anorgasmia.
 

Patients who were prescribed the drug in the form of sterile aqueous suspensions noted the development of such side effects:
 
The gastro-intestinal tract: nausea, epigastric pain, flatulence.
 

In the Central and peripheral nervous system: impaired sleep and wakefulness, irritability, emotional lability, headache, dizziness.
 

From the musculoskeletal: muscle weakness, back pain, arthralgia.
 

With the genitourinary system and breast: amenorrhea, vaginitis, leucorea, pain in the pelvis, dysfunctional uterine bleeding, breast tenderness, galactorrhea. In addition, it may decreased libido and anorgasmia.
 

Allergic reactions: skin rash, itching, hives.
 

Other: alopecia, hirsutism, acne, increased body temperature, weight change, Crescent-shaped face.
 

The drug can affect the results of the histopathological studies of the endometrium or the cervix, therefore, should warn the physician conducting the study, the drug Depo-provera.
 
In addition, when use of the drug may change in laboratory parameters, including a decrease in the level of steroid hormones and gonadotropins in the blood and urine, and globulin, linking sex hormones.
 
Contraindications:
 
Increased individual sensitivity to product components.
 
The drug is not prescribed to women during pregnancy, and also at bleedings from the vagina of uncertain etiology.
 
The drug is contraindicated in patients with severely impaired liver function.
 
The drug should not be administered before the onset of the menstrual cycle.
 
In appointing the drug as a contraceptive, it should only exclude the presence of malignant tumors of the breast (in the presence of breast cancer the drug is not used as contraceptives).
 
The drug should be used with caution in patients with epilepsy, migraine, asthma, and chronic renal and heart failure.
 
In addition, caution should be exercised when prescribing the drug to patients with diabetes, depressive States in history (with the development of severe depression, the drug should be discontinued).
 
The drug is contraindicated in women during pregnancy. The appointment of a drug should be deleted pregnancy.
 
The use of medroxyprogesterone acetate during the first trimester of pregnancy can lead to the development of neonatal pathologies and low birth weight.
 
After the drug recovery of reproductive function occurs within an average of 10 months (depending on the personal characteristics of women was observed restoration of fertility through 4-31 months after discontinuation of the drug Depo-provera).
 
The drug is excreted in breast milk, before use of the drug during lactation should consult with your doctor.
 
Interaction with other medications and alcohol:
 
With the concomitant use of high doses of the drug aminoglutethimide, with a marked decrease in the plasma concentrations of medroxyprogesterone acetate and reduced efficiency of aminoglutethimide.
 
Composition and properties:
 
1ml of sterile aqueous suspension contains:
 
Medroxyprogesterone acetate – 150mg

 

Write a review

Your Name:


Your Review: Note: HTML is not translated!

Rating: Bad           Good

Enter the code in the box below:



 
Actual categories: Allergies, Anesthesia, Antibiotics, Cardiovascular, Contraception, Dental and mouth, Gastrointestinal and liver disorders, Neurology, Сolds and upper respiratory infections Our suppliers are world famous brands, such as Actavis, Balkanfarma, Sanofy Aventis Pharma, Janssen, Alcon Pharmaceuticals, Boots Healthcare International, DHU, Ferrer Int., Chinoin and many others With our help You can buy Actovegin tablets 200mg No. 50, Actovegin for injection 80mg/ml ampoules 2ml #25, Cerebrolysin (inj.) 1ml 215.2 mg #10, IRS 19 Nasal spray, Essentiale N ampoules 250mg/5ml #5, Solcoderm ampoules 0,2 ml #1, Solcoseryl solution for injections of 42.5 mg/ml ampoules 5ml #5, Yarina tabl. #21, Phezam blisters 400mg/25mg #60, Detralex tablets 500mg #30 and more!
MS TRADE LLP Address: IFC World Trade Center Tower 42, 25 Old Broad Street, London, England

telephone